Pig Kidneys Are Bridging Patients to Human Transplants

More than 100,000 people in the United States are waiting for an organ transplant, and over 90,000 of them need a kidney. Thousands die each year before a donor organ becomes available, and the shortage has pushed scientists towards an extraordinary solution: organs from genetically modified pigs. In March 2024, surgeons at Massachusetts General Hospital in Boston transplanted the first gene-edited pig kidney into a living patient, 62-year-old Rick Slayman, who lived with it for 52 days. The results improved quickly. In January 2025, Tim Andrews received a pig kidney with 69 genetic edits and lived without dialysis for 271 days, a record, before receiving a human kidney in January 2026, the first time a pig organ has served as a bridge to a human transplant. The case was published in The Lancet in September 2026.
What the Evidence Shows
The science is careful and the path is slow. Pig organs are edited to remove genes that trigger immediate rejection and to add human genes that calm the immune system, while other edits switch off viruses embedded in the pig genome. The procedures take place under strict oversight from the United States Food and Drug Administration, first as compassionate-use cases for patients with no other option, and now as formal clinical trials. United Therapeutics began a trial of its ten-edit kidney in 2025, and the FDA cleared the first trial of a genetically engineered pig heart in May 2026. Questions remain about long-term survival, infection risk and cost, and about the ethics of raising animals for organs. But for patients on dialysis with no donor in sight, the field offers something that was missing for decades: a realistic hope. Reporting and analysis from sources such as Nature track the same developments, and specialists following pig kidney transplants say the direction is now consistent across independent lines of evidence.
The Wider Context
The wider context is a research landscape in which replication and open data now decide reputations. Findings connected to pig kidney transplants are being checked by independent groups with shared datasets, and the teams involved publish their methods in full so rivals can test every step. That discipline is slower than a headline cycle, but it is why results in this area increasingly survive first contact with scrutiny.
What Happens Next
What happens next in the story of pig kidney transplants will be decided by follow-up work already under way: larger samples, longer observation and instruments that have not yet come online. The researchers involved are unusually united on one point, that the current results justify the next investment of time and money. Readers will not have to wait long for the first tests of that claim. You can follow related developments in our coverage of science.
None of this will be settled by a single announcement, study or product launch. The pattern to watch is accumulation: independent confirmations, honest reporting of failures and steady improvement in the underlying numbers. Readers who follow those signals, rather than the loudest claim of the week, will understand this subject better than most of the commentary surrounding it suggests is possible.



